Published in Proc Natl Acad Sci U S A on January 20, 2015
Evolutionary determinants of cancer. Cancer Discov (2015) 1.19
Classifying the evolutionary and ecological features of neoplasms. Nat Rev Cancer (2017) 1.07
Epithelial-mesenchymal transition: a new target in anticancer drug discovery. Nat Rev Drug Discov (2016) 0.98
[Novel pharmaceutical treatment approaches for gastric cancer]. Pathologe (2017) 0.88
Cancer Stem Cell Plasticity Drives Therapeutic Resistance. Cancers (Basel) (2016) 0.86
Clinical impact of tumour biology in the management of gastroesophageal cancer. Nat Rev Clin Oncol (2016) 0.81
Suppression of prostate cancer progression by cancer cell stemness inhibitor napabucasin. Cancer Med (2016) 0.81
Anti-Cancer Stem-like Cell Compounds in Clinical Development - An Overview and Critical Appraisal. Front Oncol (2016) 0.80
Embryonic stem cell preconditioned microenvironment suppresses tumorigenic properties in breast cancer. Stem Cell Res Ther (2016) 0.79
Overcoming chemo/radio-resistance of pancreatic cancer by inhibiting STAT3 signaling. Oncotarget (2016) 0.78
Heparan sulfate hexasaccharide selectively inhibits cancer stem cells self-renewal by activating p38 MAP kinase. Oncotarget (2016) 0.78
Cancer stem cells: Targeting the root of cancer relapse. Nat Rev Drug Discov (2015) 0.78
Cancer stem cells: Role in tumor growth, recurrence, metastasis, and treatment resistance. Medicine (Baltimore) (2016) 0.78
Functional significance of CD105-positive cells in papillary renal cell carcinoma. BMC Cancer (2017) 0.77
Novel function of MDA-9/Syntenin (SDCBP) as a regulator of survival and stemness in glioma stem cells. Oncotarget (2016) 0.77
Oncostatin M promotes cancer cell plasticity through cooperative STAT3-SMAD3 signaling. Oncogene (2017) 0.75
Revisiting CDK Inhibitors for Treatment of Glioblastoma Multiforme. Drugs R D (2017) 0.75
STAT3 activation in infection and infection-associated cancer. Mol Cell Endocrinol (2017) 0.75
Tumor-Initiating Cells: Emerging Biophysical Methods of Isolation. Curr Stem Cell Rep (2016) 0.75
Mutations in the linker domain affect phospho-STAT3 function and suggest targets for interrupting STAT3 activity. Proc Natl Acad Sci U S A (2015) 0.75
Molecular targets in urothelial cancer: detection, treatment, and animal models of bladder cancer. Drug Des Devel Ther (2016) 0.75
Potent EMT and CSC Phenotypes are Induced by Oncostatin-M in Pancreatic Cancer. Mol Cancer Res (2017) 0.75
Drug-Loaded Polymeric Nanoparticles for Cancer Stem Cell Targeting. Front Pharmacol (2017) 0.75
Alternative therapies for metastatic breast cancer: multimodal approach targeting tumor cell heterogeneity. Breast Cancer (Dove Med Press) (2017) 0.75
Effects of U0126 and MK2206 on cell growth and re-growth of endometriotic stromal cells grown on substrates of varying stiffness. Sci Rep (2017) 0.75
Identification of metastasis-associated genes in colorectal cancer using metaDE and survival analysis. Oncol Lett (2015) 0.75
Tumor-Initiating Cells: a criTICal review of isolation approaches and new challenges in targeting strategies. Mol Cancer (2017) 0.75
STAT3 and ERK pathways are involved in cell growth stimulation of the ST2/IL1RL1 promoter. FEBS Open Bio (2017) 0.75
A comprehensive analysis of coregulator recruitment, androgen receptor function and gene expression in prostate cancer. Elife (2017) 0.75
Overview of Cancer Stem Cells and Stemness for Community Oncologists. Target Oncol (2017) 0.75
The Use of Endometrial Cancer Patient-Derived Organoid Culture for Drug Sensitivity Testing Is Feasible. Int J Gynecol Cancer (2017) 0.75
Combination therapy targeting BCL6 and phospho-STAT3 defeats intra-tumor heterogeneity in a subset of non-small cell lung cancers. Cancer Res (2017) 0.75
Overcoming Tamoxifen Resistance of Human Breast Cancer by Targeted Gene Silencing using Multifunctional pRNA Nanoparticles. ACS Nano (2016) 0.75
Chemotherapy for advanced gastric cancer: future perspective in Japan. Gastric Cancer (2016) 0.75
YM155 as an inhibitor of cancer stemness simultaneously inhibits autophosphorylation of epidermal growth factor receptor and G9a-mediated stemness in lung cancer cells. PLoS One (2017) 0.75
Prostate Cancer Stem Cell Markers Drive Progression, Therapeutic Resistance, and Bone Metastasis. Stem Cells Int (2017) 0.75
Repurposing itraconazole as an anticancer agent. Oncol Lett (2017) 0.75
Cancer recurrence monitoring using hyperpolarized [1-(13)C]pyruvate metabolic imaging in murine breast cancer model. Magn Reson Imaging (2017) 0.75
The Implications and Future Perspectives of Nanomedicine for Cancer Stem Cell Targeted Therapies. Front Mol Biosci (2017) 0.75
Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A (2003) 59.17
Stem cells, cancer, and cancer stem cells. Nature (2001) 50.27
Identification of human brain tumour initiating cells. Nature (2004) 38.87
A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature (2006) 24.52
A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature (1994) 21.59
Identification of pancreatic cancer stem cells. Cancer Res (2007) 18.36
Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer (2008) 18.08
Stat3 as an oncogene. Cell (1999) 17.39
Tumour stem cells and drug resistance. Nat Rev Cancer (2005) 15.21
Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A (2007) 13.58
Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A (2007) 11.94
Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst (2008) 11.93
Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ (2007) 8.08
Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol (2010) 7.73
Module map of stem cell genes guides creation of epithelial cancer stem cells. Cell Stem Cell (2008) 7.69
Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell (2011) 7.30
Transcription factors as targets for cancer therapy. Nat Rev Cancer (2002) 7.27
Cancer drug resistance: an evolving paradigm. Nat Rev Cancer (2013) 6.77
The role of STATs in transcriptional control and their impact on cellular function. Oncogene (2000) 6.42
Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med (2006) 5.92
Tumour heterogeneity and cancer cell plasticity. Nature (2013) 5.47
The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors. J Clin Invest (2011) 4.41
Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev Cancer (2014) 3.70
The developing cancer stem-cell model: clinical challenges and opportunities. Lancet Oncol (2012) 2.83
CD24(+) liver tumor-initiating cells drive self-renewal and tumor initiation through STAT3-mediated NANOG regulation. Cell Stem Cell (2011) 2.83
A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood (2001) 2.71
Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell (2009) 2.60
ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma. PLoS One (2011) 2.49
Cancer stem cell and cancer stemloids: from biology to therapy. Cancer Biol Ther (2007) 1.74
Selective activation of STAT5 unveils its role in stem cell self-renewal in normal and leukemic hematopoiesis. J Exp Med (2005) 1.72
TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells. Cell Stem Cell (2010) 1.64
A noncanonical Frizzled2 pathway regulates epithelial-mesenchymal transition and metastasis. Cell (2014) 1.44
Nonadhesive culture system as a model of rapid sphere formation with cancer stem cell properties. PLoS One (2012) 1.27
Emerging insights into resistance to BRAF inhibitors in melanoma. Biochem Pharmacol (2013) 1.24
Constitutive activation of signal transducer and activator of transcription 3 (STAT3) and nuclear factor κB signaling in glioblastoma cancer stem cells regulates the Notch pathway. J Biol Chem (2013) 1.24
Cancer stem cells--important players in tumor therapy resistance. FEBS J (2014) 1.23
Concise review: The Sox2-Oct4 connection: critical players in a much larger interdependent network integrated at multiple levels. Stem Cells (2013) 1.17
Drug resistance: challenges to effective therapy. Curr Cancer Drug Targets (2011) 1.17
Cancer stem cells and tumor response to therapy: current problems and future prospects. Semin Radiat Oncol (2009) 1.13
Ionizing radiation induces stemness in cancer cells. PLoS One (2012) 1.12
Treatment resistance in stem cells and breast cancer. J Mammary Gland Biol Neoplasia (2009) 1.10
Concise review: pursuing self-renewal and pluripotency with the stem cell factor Nanog. Stem Cells (2013) 1.00
Recent understanding of the molecular mechanisms for the efficacy and resistance of EGF receptor-specific tyrosine kinase inhibitors in non-small cell lung cancer. Expert Opin Ther Targets (2012) 0.96
Induction of cancer cell stemness by chemotherapy. Cell Cycle (2012) 0.93
Model of tumor dormancy/recurrence after short-term chemotherapy. PLoS One (2014) 0.88